Product Description
Mechanisms of Action: PDE4 Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intravenous
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Multiple Sclerosis
Phase 1: Huntington Disease|Depressive Disorder|Depressive Disorder, Major|Brain Diseases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
000824-M | P1 |
Terminated |
Depressive Disorder |
2023-02-08 |
|
06-M-0215 | P1 |
Completed |
Depressive Disorder, Major |
2016-06-16 |
|
NCT01602900 | P1 |
Completed |
Huntington Disease |
2012-04-12 |
|
06-M-0002 | P1 |
Completed |
Brain Diseases |
2009-02-05 |